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Abstract
Background: The concept of combinatorial biomarkers was conceived
around 2010: it was noticed that simple biomarkers are often inadequate
for recognizing and characterizing complex diseases.
Methods: Here we present an algorithmic search method for complex
biomarkers which may predict or indicate Alzheimer’s disease (AD) and other
kinds of dementia. We applied data mining techniques that are capable to
uncover implication-like logical schemes with detailed quality scoring. Our
program SCARF is capable of finding multi-factor relevant association rules
automatically. The new SCARF program was applied for the Tucson, Ari-
zona based Critical Path Institute’s CAMD database, containing laboratory
and cognitive test data for more than 6000 patients from the placebo arm of
clinical trials of large pharmaceutical companies, and consequently, the data
is much more reliable than numerous other databases for dementia.
Results: The results suggest connections between liver enzyme-, B12 vita-
min -, sodium- and cholesterol levels and dementia, and also some hemato-
logic parameter-levels and dementia.
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1. Introduction
Dementia is a major problem presently of high-income countries and also
an increasing concern of low-income nations worldwide. Though sporadic
before the age of 60, its occurrence is doubled by every five years of age
thereafter (Bermejo-Pareja et al., 2008; Carlo et al., 2002). About 40 percent
of the population over 90 are affected, and up to 20 percent of those between
75 and 84 suffer from this condition (Wortmann, 2012; Prince and Jackson,
2009). The most common cause of dementia is Alzheimer’s disease (AD).
The earliest symptoms of AD include memory problems; disorientation in
time and space; and difficulty with calculation, language, concentration and
judgment. As the disease evolves, patients may develop severe behavioral
abnormalities and may even become psychotic. In the final stages of the
disease the sufferers are incapable of self-care and become bed-bound, for
years or even decades.
The diagnosis of AD in the great majority of the cases is done by clinical
criteria, using standardized questionnaires (Mossello et al., 2010). Generally
accepted evidences show that neuropathological damage begins more than
20 years before those clinical signs (Jack et al., 2009), and by the time it is
diagnosed, a large part of the neurons are already irreversibly lost.
In the last years, by the combination of cerebrospinal fluid analysis, clin-
ical signs and neuroimaging techniques a quite reliable diagnostic method
emerged (Dubois et al., 2007). The method, however, is prohibitively ex-
pensive, is not an early warning-type biomarker, and does not seem to be
applicable for wide-scale screening of the senior population.
Very recently, using the combination of usual clinical laboratory data, cog-
nitive impairment questionnaires and blood-based proteomics assays was re-
ported to reliably diagnose AD, without neuroimaging or cerebrospinal fluid
assays (O’Bryant et al., 2010, 2011). However, early warning biomarkers are
still need to be found.
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The final goal of ours is finding new combinatorial biomarkers for Alzheimer’s
disease. In this paper we report our results that may be used to reach this
final goal; but presently we are able to show only that certain sets of labo-
ratory data may make dementia (and not AD) more probable, and certain
other sets may make dementia less probable.
There are several large databases on Alzheimer’s disease available for re-
searchers. The quality of their data obviously depends on the methodology
of the research that produced the database in question. The most well-
organized, strictly overseen and rigorously documented experiments are per-
haps conducted by the order of large pharmaceutical companies in hospitals
and clinics in phase 1, 2 and 3 drug trials. Unfortunately, the detailed re-
sults of those trials are seldom published (especially those corresponding to
unsuccessful drug trials) since they are owned by the companies that ordered
the trials.
In their Alzheimer’s disease database the Tucson, Arizona based Critical Path
Institute made available the results of the placebo arm of numerous multi-
million dollar clinical trials conducted by the order of large pharmacological
companies (Romero et al., 2009, 2010; Rogers et al., 2012). The data of the
placebo line of the trials does not contain proprietary information concerning
the effects of the novel drugs under trial, but it does contain reliable, well-
organized laboratory and cognitive test-data, presumably in much higher
quality than other, larger, but perhaps less strictly conducted and controlled
studies for AD.
Data used in the preparation of this article have been obtained from the
Coalition Against Major Diseases (CAMD) database (Romero et al., 2009).
In 2008, Critical Path Institute, in collaboration with the Engelberg Cen-
ter for Health Care Reform at the Brookings Institution, formed the Coali-
tion Against Major Diseases (CAMD). The Coalition brings together pa-
tient groups, biopharmaceutical companies, and scientists from academia,
the US Food and Drug Administration (FDA), the European Medicines
Agency (EMA), the National Institute of Neurological Disorders and Stroke
(NINDS), and the National Institute on Aging (NIA). Coalition Against Ma-
jor Diseases (CAMD) includes over 200 scientists from member and non-
member organizations. The data available in the CAMD database have been
volunteered by both CAMD member companies and non-member organiza-
tions.
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In contrast with more conservative statistical methods, we applied data min-
ing techniques for data analysis and combinatorial biomarker search. Data
mining, as defined in (Hand et al., 2001), is the analysis of large observational
sets of data for finding new, still unsuspected relations with novel, usually
high-throughput methods. Frequently, data mining uses large data sets orig-
inally collected for uses other than the data mining analysis (Hand et al.,
2001).
Simple biomarkers (e.g., the high level of glucose in diabetes) show a physi-
ological condition, related to the appearance or the status of a disease. The
concept of combinatorial biomarkers appeared around 2010, and numerous
authors simply use the term in the following sense: If—say—the high con-
centration of all the molecules A, B and C characterizes a certain condition
X well (and the high concentration of any subset of the set {A,B,C} would
not), then they say that {A,B,C} is a combinatorial biomarker of the condi-
tion X (Wu et al., 2012). In (O’Bryant et al., 2011), by applying proteomics
assays, a 30-protein set was identified as a combinatorial biomarker of AD.
We intend to discover more involved combinatorial biomarkers that may con-
tain clinical laboratory data and psychiatric test data, and we count not only
on positive findings (i.e., high concentration or appearance of a certain value),
but also the lack thereof (i.e., normal or low concentration). We start with
frequent item set analysis, then apply association rule mining (Hand et al.,
2001). We apply a new methodology that discovers complex combinatorial
biomarkers only if these complex biomarkers have stronger implications than
the simpler biomarkers.
Therefore, our program SCARF will not produce artificially complex
biomarkers: the more complex the new biomarker, the more valid the new
implication.
1.1. Association Rule Mining
Our research group was among the first applying association rule mining in
molecular biology (Ivan et al., 2007). Recently, association rule mining has
been gaining applications in drug discovery (Galustian and Dalgleish, 2010),
in the design of clinical trials (Epstein, 2009), and most recently, also in
image analysis in Alzheimer’s research (Chaves et al., 2011).
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Association rule mining is a field of data mining (Hand et al., 2001) developed
by marketing experts for discovering implication-like rules in uncovering cus-
tomer behavior (Agrawal et al., 1993), without a priori assumptions on this
behaviour. We intended to apply this method for laboratory and cognitive
test data from the CAMD database (Romero et al., 2009).
We analyzed how the presence/absence/severity of cognitive impairment
could be detected from combinations of known biomarkers, demographic in-
formation and measurements of vital signs. As an example, consider this
expression:
sodium = high & (protein = high or age ≥ 60)→ mmse total ≤ 15 (1)
Here & stands for logical AND. This rule states that if blood sodium is high,
AND urine protein is high OR age is at least 60, then the total MMSE (Mini
Mental State Examination) score will be at most 15 out of 30. Let us call the
left-hand side of the expression (abbreviated by LHS) a combinatorial marker
of the right-hand side (abbreviated by RHS). Thus the statement above can
be reformulated as follows: high serum sodium combined with either high
urine protein or age of at least 60 is a marker of a total MMSE score less
than or equal to 15.
An expression consists of elementary clauses combined by logical operators.
These elementary clauses may include equalities and inequalities. By substi-
tuting all elementary clauses with some wildcard, we can obtain the pattern of
an expression. For example, the expression above is of the following pattern:
 & ( or )→  (2)
During our analysis we started with a given pattern like the one above. Then
we considered all the possible logical expressions according to this pattern,
and assigned numerical values to them that indicated the reliability and
validity of the logical rules. Then we filtered and sorted the vast amount
of possible rules according to these numerical criteria, and selected the best
ones. We changed a simpler rule to a more complex rule only if the more
complex rule had higher reliability/validity than the simpler rule (see the
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next section for the exact definitions).
2. Materials and Methods
Our data source, which will be referred to as CAMD from now on
(Romero et al., 2009), was provided by the Coalition Against Major Dis-
eases, and consisted of the placebo arm of several drug trials. Over 6000
subjects participated in these trials including demented and not demented
people of various age and sex (see Table 1) for basic statistics). Standard
laboratory data that have been collected for the subjects included about
300 different values in blood or urine altogether. These values were gener-
ally measured multiple times per subject (on different visit days), though
each person was tested for only about 30 different values. The cognitive and
psychological status of the subjects was measured at different times by stan-
dardized questionnaires ADAS-COG, ADCS-ADL, MMSE, NPI and SIB. In
addition, some genetic tests have been performed, e.g., ApoE and MTHFR
genotypes were recorded. Vital sign measurements (BP, pulse rate, respira-
tory rate and body temperature) have also been taken. Results concerning
this dataset will be described in greater detail below.
We transformed this large dataset into a conveniently processable form. The
CAMD database contained several rows describing one person and these were
scattered between multiple data tables. So we collected the essential data
from CAMD into one single table: this simplified table contained only one
row for each subject.
If a subject was tested on different visit days, then we took the average of
these test results. The resulting main table for CAMD consisted of around
170 columns (record fields) and 6000 rows (entries).
Our main method of processing the resulting table was association rule min-
ing. First, we took a given pattern like  & ( or ) → . Notice that
the LHS (Left Hand Side) is in conjunctive normal form here (multiple OR
clauses ANDed together). This pattern can be encoded as “1 2”, as the first
OR clause has one sub-clause and the second one has two. This pattern
matches all statements of the following kind: “if property A is present and
property B or property C is present, then property D is present”.
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Since we are interested in implication-like association rules that indicate fac-
tors implying normal or demented mental state, we made restrictions on
which data columns can occur on the LHS (Left Hand Side) and the RHS
(Right Hand Side). Laboratory data and sex were allowed on the LHS, and
columns directly indicating mental status on the RHS. Then we gave numer-
ical constraints on the “goodness” of a rule—thus introducing an ordering on
the rules. Finally we tried to fill in all the void boxes in all possible ways to
find the best rules.
If done without any optimization, this process would have yielded a vast
amount of different rules that would have needed to be evaluated “by hand”.
Even just enumerating all the possible matches to this pattern would have
required enormous computational resources. Consequently, we needed to
make the computation feasible: we used a branch-and-bound approach similar
to the Apriori Algorithm (Hand et al., 2001): if certain values for the first two
boxes made a rule fail our constraints—regardless of what would be written
in the third box—, then we threw out the rule and did not bother checking
all the possible values for the third box. (A good analogue would be cutting
a tree in a clever way: one does not bother removing all the little twigs one
by one, but rather cuts the trunk.) This technique saved us considerable
computational time, and made possible this study.
The association rule mining was done with our own program written in the
C++ programming language, named SCARF (Simple Combinatorial Asso-
ciation Rule Finder). We calculated various standard numerical values for
all association rules, which would indicate their validity. First, we defined
the universe of a rule: this is the set of the database rows where all columns
present in the rule have a known value. As we mentioned before, not all sub-
jects were tested for everything, so our database contained a large amount
of N/A entries. For testing the validity of a rule, only those rows could be
taken into account, where there is no N/A written to any of the columns
participating in the rule.
For evaluating the validity of a rule, we continued to work with only its
universe and temporarily discarded all other rows in the database. Next, we
calculated the LHS support, RHS support and support of a rule. The LHS
support is the number of the rows where the LHS is true, the RHS support is
the number of the rows where the RHS is true, and the support is the number
of the rows where both the LHS and the RHS are true.
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Then, we calculated the confidence, lift, leverage and χ2-statistic for a rule.
The confidence is defined as the conditional probability of the RHS, assuming
that the LHS is true. If one has high serum sodium combined with high
urine protein or age at least 60 in our example, then confidence describes the
chance of having a low MMSE score. The lift shows how many times the
presence of the LHS increases the probability of RHS. Generally it indicates
how big a risk factor the LHS is—though it is not certain that the LHS
causes the RHS, as they both may be only consequences of some background
phenomenon (Hand et al., 2001).
The leverage is the difference between the observed probability of both the
LHS and RHS being true, and the estimated probability we get by assuming
that the LHS and RHS are independent events. It indicates the level of de-
pendency between the LHS and the RHS in a way. Finally, the χ2-statistic is
a well-known measure of the estimated dependence of the indicator variables
of the LHS and RHS. The p-value output by SCARF comes from this χ2 test.
The E-value (also calculated by SCARF) equals to the p-value multiplied by
the total number of possible rules. The E-value is a more useful measure of
randomness, since if we examine many rules, there is a high probability that
the p-value will be small enough, while the E-value is insensitive for this kind
of artifact.
The following table formalizes some of the above definitions. Here P denotes
the probability measure, and P (A|B) denotes the conditional probability of
event A on condition B:
Confidence = P (RHS|LHS)
Lift =
P (RHS|LHS)
P (RHS)
Leverage = P (RHS ∧ LHS)− P (RHS)P (LHS)
For the CAMD database the acceptable values were set as follows: universe ≥
500, support ≥ 50, confidence ≥ 0.5, lift ≥ 1.2, p− value ≤ 0.05. In partic-
ular, we recorded rules on data that were measured on at least 500 subjects.
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We defined the goodness of a rule to be equal to its lift.
Therefore we listed association rules of lift at least 1.2, i.e., only those rules
were listed where the LHS increased the probability of RHS with at least
20%.
One of the most significant novelties in our approach was filtering out those
rules which were too complicated. The SCARF program threw out elemen-
tary clauses from the LHS as long as the overall goodness (i.e. the lift) of
the rule did not decrease by more than 2%. Then it deleted the whole rule if
its numerical values dropped below our constraints during the simplification
process. In other words, we sacrificed some of the lift for simplicity, to avoid
overfitting.
Having listed the best rules, we also tried to determine whether the elemen-
tary clauses (like lb ast = h, lb folate = l, etc.) have positive or negative
effect on mental state. Therefore we counted their appearances on LHS, and
classified these occurrences by the nature of the RHS: does it indicate normal
cognition or rather dementia? We counted how many times an elementary
clause occurred on the LHS of a rule when the RHS indicated a positive men-
tal state, and how many times it occurred in rules where the RHS showed a
negative state. Thus, in addition to mining rules whose LHS could probably
serve as good combinatorial risk factor of dementia, we estimated the contri-
bution of the individual clauses, for example “protein=high” to the onset of
cognitive impairment.
For an elementary clause, Positive score was the number of rules with positive
RHS, and Negative score was the number of rules with negative RHS. Then
we compared Positive score with Negative score : by subtracting the negative
score from the positive score we got a value called simply the score of the
clause. Those elementary clauses whose score was positive were called positive
clauses, and similarly, those where the score was negative were called negative
clauses.
To summarize our method: we searched for combinatorial biomarkers us-
ing a branch-and-bound algorithm for association rule mining; then made
statistical analysis regarding elementary clauses.
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3. Results
The program outputs 725 rules from the CAMD database. Selected rules,
ordered by lift (i.e. “goodness”) decreasing are listed in Table 2. The whole
set of rules is presented as Table S1 of the online supporting material.
On the LHS, clauses concerning biomarkers end in “=l”, “=h”, “=n”, or com-
binations of these. Here l means low, h means high and n means normal.
If there are multiple letters (such as nh), then the corresponding equality
states that the value is either high or normal. In other words, single letters
correspond to a value category, while multiple letters mean the union of these
categories.
For example, the second rule in Table 2 was that of the second best lift. It
can be interpreted in the following way: It is likely that if serum sodium level
is elevated, and serum glucose level is either too low or normal, then the total
MMSE score will be less than 15. Note that it is true for all rules of ours
that there is not necessarily a causal relation between the LHS and RHS, as
both the LHS and RHS can be consequences of an unknown process in the
background.
The third rule states that“if serum sodium level is elevated, and calcium level
is either low or normal, then MMSE orientation subscore will be at most 2”.
The seventh rule in Table 2 states that “if serum sodium level is elevated,
and body temperature is too low, then total MMSE score will be less than
15”.
From these selected rules we can conclude that elevated sodium combined
with various other factors (not too high glucose, not too high calcium, low
temperature) might be a good indicator (or even the cause) of mental decline.
Elementary clauses with the greatest positive effect on normal cognition are
listed in Table 5.
Elementary clauses with the greatest negative effect on normal cognition are
listed Table 6.
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4. Discussion
Among the 725 rules identified, 513 had lift values exceeding 2.00. Most of
the rules exceeding even the 3.00 lift value had one thing in common: the
LHS contained the premise lb sodium = h.
4.1. Liver function
The rules found suggest that having high serum levels of AST (aspartate
aminotransferase), as well as having low or high serum levels of ALT (ala-
nine aminotransferase) may predispose to an impaired cognition character-
ized by low mini mental state examination (MMSE) scores. It should be
noted that low ALT was much more rare in the CAMD database than high
ALT, so the negative effect should be attributed mainly to high ALT. How-
ever, serum ALP (alkaline phosphatase) levels seem to have a controversial
effect on mental status.
AST, ALT and ALP levels derive from the liver. Elevated ALP might indicate
bile duct obstruction. AST or ALT may elevate in a number of cases of liver
injury or damage, spreading from acute or chronic viral infections to alcohol
induced or non-alcoholic steatohepatitis. It is interesting to note that elevated
serum levels of AST (more than those of ALT) have been associated with
impaired mental status. Although mild elevations in serum levels of AST
and ALT are nonspecific to the etiology of liver injury, certain alteration
patterns in these parameters may reflect the nature of the hepatic disease.
For instance, the value of the AST/ALT ratio—also known as the De Ritis
ratio—is approximately 0.8 in normal subjects, a ratio exceeding 2.00 being
suggestive to alcoholic hepatitis.
Therefore we scanned the subjects with high AST values for higher than 2
AST/ALT ratio: we have only found 10 subjects satisfying both conditions.
In addition, only 2 rules had AST/ALT on the left-hand side. Consequently,
we may assume that high serum AST in the study subjects is not typically
accompanied with high De Ritis ratio (i.e. probable alcoholic hepatitis).
The association of impaired liver function with mental decline can be illu-
minated in two perspectives. On one hand, impaired liver function might
be insufficient to prevent the brain from the effects of certain neurotoxins,
e.g. ammonia. This happens in the case of hepatic encephalopathy (HE),
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when severe liver damage resulting in acute liver insufficiency cannot detox-
ificate ammonia and other neurotoxins. On the other hand, the association
of elevated AST/ALT ratio with impaired mental status proposes that an-
other obscure element (e.g. chronic alcohol consumption) might be the factor
responsible for both cognitive and metabolic damages.
Our results raise the possibility of a pathogenetic linkage between liver func-
tion and mental status in patients with AD. Such linkage has also been
proposed by other studies (Sutcliffe et al., 2011; Astarita et al., 2010). One
study concludes that peripheral reduction of β-amyloid is sufficient to reduce
brain β-amyloid and proposes that β-amyloids, which are of major pathogenic
importance in AD may originate from the liver (Sutcliffe et al., 2011). An-
other research found that deficient liver production of docosahexaenoic acid
(a neuroprotective fatty acid) correlates with impaired cognitive status in
AD patients (Astarita et al., 2010).
To rule out the possibility when the elevated AST level is due to some med-
ications taken, we compiled a detailed Table S3 (in the supporting on-line
material) containing the number of subjects taking certain drugs, and the
number of drug-takers with high AST. The data shows that, for example,
1929 subjects took Donepezil, while among the Donepezil-takers, only 415
have had high AST levels.
4.2. Serum sodium
A great number of rules (224) have high sodium on the left hand side, all
of which have impaired cognition on the right hand side. Net water loss is
responsible for the majority of cases of hypernatremia (Adrogue and Madias,
2000). A recent publication, examining the causes and comorbidities in
patients older than 65 years, has found that the most common cause of
community-acquired hypernatremia is dehydration due to reduced oral in-
take (Turgutalp et al., 2012). More interestingly, they found that the most
common comorbidity in this patient group was AD, present in 31.4% of pa-
tients with hypernatremia (Turgutalp et al., 2012). Hydration status has a
significant impact on the volume of grey and white matter in the brain and
on the quantity of cerebrospinal fluid as a hallmark of ventricular enlarge-
ment (Streitbuerger et al., 2012). The pattern of shrinkage in white matter
volume and increase of the ventricular system due to dehydration is consis-
tent with the structural brain changes observed during the progression of
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AD (Streitbuerger et al., 2012). In another study, patients with AD under-
went bioelectrical impedance vector analysis to assess the body cell mass and
hydration status related to AD (Buffa et al., 2010). Results demonstrated
a tendency towards dehydration in patients with AD (Buffa et al., 2010).
Although the association of dehydration and AD is supported by these pub-
lications, the specific pathogenic nature of this association remains obscure
(Turgutalp et al., 2012; Streitbuerger et al., 2012; Buffa et al., 2010).
4.3. Vitamin B12
Our results were able to present the beneficial impact of high levels of vita-
min B12, also known as cobalamin, on cognition. Along with folate, vitamin
B12 has an important role in the maintenance of genome integrity (Fenech,
2012). Although previous publications found association of low serum levels
of vitamin B12 and AD (Malaguarnera et al., 2004; McCaddon et al., 2004),
a recent systemic review on vitamin B12 status and cognitive impairment
fails to declare a clear association between vitamin B12 status and dementia
(O’Leary et al., 2012). However, this review also found that studies using
newer and more specific biomarkers of vitamin B12 status such as methyl-
malonic acid and holotranscobalamin were able to draw an association be-
tween mental decline and poor vitamin B12 status (O’Leary et al., 2012).
Although clinically vitamin B12 deficiency may result in macrocytic anaemia,
in the case of AD patients the occurrence of macrocytic anaemia is rare and
the neurological and hematological features are unrelated (McCaddon et al.,
2004).
4.4. Hematological parameters
Additional interesting rules were detected regarding hematological param-
eters. In particular, independently from each other, high values of mean
corpuscular hemoglobin (MCH), low values of mean corpuscular hemoglobin
concentration (MCHC), and low values of mean corpuscular volume (MCV)
were also associated with high MMSE scores. Although high values of MCH
and low values of MCHC are present in the case of macrocyctic anaemia
(with the addition of high levels of mean corpuscular volume, low levels of
hemoglobin and hematocrit), such solely associations should not be discussed,
as they may be coincidental.
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Among the rules with lift values exceeding 2.00, other parameters of hemato-
logical status (such as level of hemoglobin, red blood cell number, white blood
cell number) were also present. Monocyte and eosinophil levels also appear
on the left hand side of many rules with high lift. These premises appear in
combinations with various other (mostly non-hematological) premises.
4.5. Blood cholesterol and cognition
The positive or negative effects of high cholesterol values to Alzheimer’s dis-
ease and cognition is a controversial issue. Some studies (e.g., (Helzner et al.,
2009; Whitmer et al., 2005; Zambon et al., 2010)) show negative effects of
high cholesterol value for cognition, while other studies ((Reitz et al., 2004,
2005; Mielke et al., 2005)) prove the positive effects for cognition.
Our data supports both conclusions in a sense. That is, low, low-normal and
high cholesterol levels are all associated with impaired mental status, but
with a different extent (scores -21, -13 and -42, respectively). See Table 5 for
a selection of cholesterol-related rules from the larger Table S1 in the on-line
supporting material.
It is worth to note that, by Table 5, elevated, low or low-normal cholesterol
levels do not necessarily mean a higher likelihood of impaired cognition by
themselves, but only combined with high sodium.
A most recent study (Pierrot et al., 2013) shows that the neuronal expression
of amyloid precursor protein APP controls the cholesterol 24-hydroxylase
mRNA levels and decreases cholesterol turnover; therefore in certain setups,
the presence of amyloid precursor proteins imply lowered cholesterol levels.
5. Conclusions
A 6000-patient, high-quality database was analyzed with original methods
for biomarkers of dementia. We have found some novel and also some al-
ready well established relations connected to good or bad cognition in a 6000
patient database. The already established findings prove the validity of our
datamining approach, and the new findings, related to MCH, ALP and AST
levels prove its power. Some more controversial biomarkers, including choles-
terol level, were also re-discovered, and we found that the high cholesterol
levels seem to be beneficial only with combination with old age.
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Tables
Table 1: Basic statistics on the subjects of the CAMD data
Age distribution Gender distribution MMSE distribution
A: up to 65 years 1093 Female 3315 A: severe cog. impairment 255
B: 66-75 years 2070 Male 2653 B: moderate cog. impairment 611
C: 76-85 years 2408 C: mild cog. impairment 3224
D: more than 85 397 D: normal cognition 1352
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Table 2: Several association rules of the highest lift. The lift value describes the multipli-
cation factor, increasing the probability of the Right Hand Side (RHS) if the Left Hand
Side is true. For example, our best rule (the first below) is saying that one can have the
a bad result of a cognitive test with four times higher probability if one has high serum
sodium and either low cholesterol or low or normal blood glucose level.
(lb_sodium=h) & (lb_chol=l or lb_gluc=ln) ---> mm_ori=B
Universe: 2783, LHS support: 87, RHS support: 401, Support: 50
Confidence: 0.574713, Lift: 3.98859, Leverage: 0.0134618, p-value: 0, E-value: 0
3.98859
(lb_gluc=ln) & (lb_chol=l or lb_sodium=h) ---> mm_ori=B
Universe: 2783, LHS support: 105, RHS support: 401, Support: 57
Confidence: 0.542857, Lift: 3.76751, Leverage: 0.0150451, p-value: 0, E-value: 0
3.76751
(lb_sodium=h) & (lb_hct=l or lb_gluc=ln) ---> mm_ori=B
Universe: 2926, LHS support: 95, RHS support: 420, Support: 51
Confidence: 0.536842, Lift: 3.74, Leverage: 0.0127695, p-value: 0, E-value: 0
3.74
(lb_sodium=h) & (bpsys=ln or lb_gluc=ln) ---> mm_ori=B
Universe: 3091, LHS support: 102, RHS support: 425, Support: 52
Confidence: 0.509804, Lift: 3.70777, Leverage: 0.0122858, p-value: 0, E-value: 0
3.70777
(lb_gluc=ln) & (lb_creat=l or lb_sodium=h) ---> mm_ori=B
Universe: 3091, LHS support: 99, RHS support: 425, Support: 50
Confidence: 0.505051, Lift: 3.6732, Leverage: 0.0117722, p-value: 0, E-value: 0
3.6732
(lb_sodium=h) & (age=D or lb_gluc=ln) ---> mm_ori=B
Universe: 3091, LHS support: 101, RHS support: 425, Support: 51
Confidence: 0.50495, Lift: 3.67248, Leverage: 0.0120068, p-value: 0, E-value: 0
3.67248
(lb_gluc=ln) & (lb_ast=l or lb_sodium=h) ---> mm_ori=B
Universe: 3091, LHS support: 101, RHS support: 425, Support: 51
Confidence: 0.50495, Lift: 3.67248, Leverage: 0.0120068, p-value: 0, E-value: 0
3.67248
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Table 3: Some association rules involving serum cholesterol level
(lb_sodium=h) & (lb_chol=l or lb_gluc=ln) ---> mm_ori=B
Universe: 2783, LHS support: 87, RHS support: 401, Support: 50
Confidence: 0.574713, Lift: 3.98859, Leverage: 0.0134618, p-value: 0, E-value: 0
3.98859
(lb_gluc=ln) & (lb_chol=l or lb_sodium=h) ---> mm_ori=B
Universe: 2783, LHS support: 105, RHS support: 401, Support: 57
Confidence: 0.542857, Lift: 3.76751, Leverage: 0.0150451, p-value: 0, E-value: 0
3.76751
(lb_sodium=h) & (lb_chol=ln or lb_gluc=ln) ---> mm_ori=B
Universe: 2783, LHS support: 106, RHS support: 401, Support: 55
Confidence: 0.518868, Lift: 3.60102, Leverage: 0.0142747, p-value: 0, E-value: 0
3.60102
(lb_chol=h) & (lb_cl=h or lb_sodium=h) ---> mm_ori=B
Universe: 1420, LHS support: 71, RHS support: 304, Support: 51
Confidence: 0.71831, Lift: 3.35526, Leverage: 0.0252113, p-value: 2.22045e-016, E-value: 1.88773e-007
3.35526
(lb_chol=h) & (lb_monole=l or lb_sodium=h) ---> mm_total=AB
Universe: 1364, LHS support: 73, RHS support: 325, Support: 58
Confidence: 0.794521, Lift: 3.33454, Leverage: 0.02977, p-value: 1.51101e-013, E-value: 0.00012846
3.33454
(lb_sodium=h) & (lb_monole=h or lb_chol=h) ---> mm_total=AB
Universe: 1364, LHS support: 66, RHS support: 325, Support: 51
Confidence: 0.772727, Lift: 3.24308, Leverage: 0.0258608, p-value: 5.9952e-015, E-value: 5.09687e-006
3.24308
(lb_chol=h) & (lb_hbsag=h or lb_sodium=h) ---> mm_attcal=B
Universe: 1164, LHS support: 67, RHS support: 312, Support: 50
Confidence: 0.746269, Lift: 2.78416, Leverage: 0.0275268, p-value: 6.2725e-011, E-value: 0.0533262
2.78416
(lb_sodium=h) & (lb_bun=h or lb_chol=h) ---> mm_attcal=B
Universe: 1387, LHS support: 61, RHS support: 429, Support: 52
Confidence: 0.852459, Lift: 2.75609, Leverage: 0.023888, p-value: 8.87168e-012, E-value: 0.00754232
2.75609
(lb_sodium=h) & (lb_ca=l or lb_chol=h) ---> mm_attcal=B
Universe: 1420, LHS support: 61, RHS support: 460, Support: 51
Confidence: 0.836066, Lift: 2.5809, Leverage: 0.0219996, p-value: 2.52266e-011, E-value: 0.0214466
2.5809
(lb_sodium=h) & (lb_cl=h or lb_chol=h) ---> mm_attcal=B
Universe: 1420, LHS support: 66, RHS support: 460, Support: 55
Confidence: 0.833333, Lift: 2.57246, Leverage: 0.0236759, p-value: 1.65421e-010, E-value: 0.140634
2.57246
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Table 4: Legends for Table 2 and 3
age Subject age (A: ≤ 65 years, B: 66–75 years, C: 76–85 years, D: >85 years)
ast alt De Ritis ratio
bpdia Diastolic blood pressure
bpsys Systolic blood pressure
lb alb Serum albumine
lb alp Serum alkaline phosphatase
lb alt Serum alanine aminotransferase
lb ast Serum aspartate aminotransferase
lb baso Basophils, particle concentration
lb bili Serum indirect bilirubin
lb bun Blood Urea Nitrogen
lb ca Serum calcium
lb chol Serum cholesterol
lb ck Serum creatine kinase
lb cl Serum chlorine
lb creat Serum creatinine
lb eos Eosinophils, particle concentration
lb gluc Serum glucose
lb hba1c Hemoglobin A1C
lb hbsag Hepatitis B virus surface antigen
lb hct Hematocrit
lb hgb blood Blood hemoglobin
lb k Serum potassium
lb ketones Ketones
lb ldh Lactate dehydrogenase
lb lym Lymphocytes, particle concentration
lb lymle Lymphocytes/leukocytes ratio
lb mch Mean Corpuscular Hemoglobin
lb mchc Mean Corpuscular Hemoglobin Concentration
lb mcv Mean Corpuscular Volume
lb mono Monocytes, particle concentration
lb monole Monocytes/leukocytes ratio
lb neut Neutrophils, particle concentration
lb neutle Neutrophils/leukocytes ratio
lb ph pH
lb phos Phosphate
lb plat Platelets
lb prot Total protein
lb rbc blood Red blood count
lb sodium Serum sodium
lb tsh Thyrotropin
lb vitb12 Serum B12 vitamin
lb wbc blood White blood count
mm attcal MMSE attention and calculation subscore (B: 0–1, C: 2, D: 3, E: 4–5)
mm lang MMSE language subscore (B: 0–2, C: 3–4, D: 5–6, E: 7–9)
mm ori MMSE orientation subscore (B: 0–2, C: 3–4, D: 5–7, E: 8–10)
mm recall MMSE recall subscore (B: 0, C: 1, D: 2, E: 3)
mm total MMSE total score (A: <10, B: 10–14, C: 15–23, D: ≥ 24)
pulse Heart rate
resp Respiratory rate
sex Subject sex (F: female, M: male)
temper Temperature
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Table 5: Elementary clauses with the greatest positive effect on normal cognition
lb vitb12=h score: 67
lb mch=h score: 25
lb mchc=l score: 22
lb k=h score: 17
sex=M score: 10
pulse=l score: 9
lb bun=l score: 8
age=AB score: 4
lb mono=nh score: 3
resp=ln score: 3
lb plat=ln score: 2
lb eos=nh score: 2
lb prot=nh score: 2
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Table 6: Elementary clauses with the greatest negative effect on normal cognition
temper=nh score: -10
lb wbc blood=h score: -10
age=BCD score: -10
lb prot=h score: -12
lb gluc=h score: -12
pulse=h score: -12
lb ck=h score: -12
lb hct=nh score: -12
lb k=ln score: -12
lb alp=h score: -12
lb chol=ln score: -13
lb ph=h score: -13
lb hct=l score: -13
lb alt=h score: -13
age=A score: -14
bpsys=ln score: -14
lb creat=ln score: -14
lb creat=h score: -16
temper=l score: -17
lb alp=ln score: -18
lb bun=ln score: -18
lb alt=l score: -19
lb wbc blood=l score: -20
lb chol=l score: -21
pulse=nh score: -21
lb prot=ln score: -22
lb bun=h score: -22
lb plat=h score: -26
lb gluc=ln score: -27
bpdia=ln score: -28
age=CD score: -32
lb chol=h score: -42
lb ast=h score: -43
lb ca=l score: -50
sex=F score: -57
age=D score: -99
lb cl=h score: -173
lb sodium=h score: -22425
